Pharmafile Logo

Top-10 ways for Pharma to leverage AI according to…AI

- PMLiVE

Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s remarkable to see the progress made in the technology compared to only a few months ago and there are no signs of the progress slowing down.

The pharmaceutical industry has numerous use cases for AI. From the drug discovery phase to patient care, AI has the potential to enhance almost every stage of the product life cycle. Out of curiosity, I asked a generative AI model what it considers the top innovative and new ways that AI tools can be employed to enhance Pharma’s operations. With some paraphrasing, here’s what it said:

  1. Identification of biological data for drug discovery and development
  2. Analysis of patient data, including genetic information, to help develop personalized medicine
  3. Optimization of clinical trial design and execution
  4. Improved manufacturing efficiency
  5. Enhanced supply chain visibility and forecasting
  6. Analysis of real-world data to inform better decision-making
  7. Digital therapeutics and patient monitoring
  8. Help with navigating the complex regulatory landscape
  9. Market analysis and competitive intelligence
  10. Drug repurposing

Let’s dive in!

1. Drug Discovery and Development

In theory, AI can substantially reduce the time and cost of drug discovery and development in four main ways: access to new biology, improved or novel chemistry, better success rates, and quicker and cheaper discovery processes. By predicting how different compounds will react with each other and with their targets and by quickly analyzing vast amounts of biological data, AI can identify drug candidates that are more likely to succeed in clinical trials.

Unsurprisingly, the US FDA has reported a noticeable increase in the number of submissions that use AI/machine learning (ML) components in recent years; in 2021, they received more than 100 submissions wherein AI use was reported. In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%. Looking back at 2023, AI for drug discovery saw both wins and losses. Despite new partnerships and increasing traction, there were some setbacks. Notably, the AI-aided drug ulotaront, a TAAR1 agonist developed for the treatment of schizophrenia, failed its two Phase 3 studies.

2. Personalized Medicine

AI can help develop precision medicine by analyzing patient data, including demographic, clinical, and genetic information, as well as information about their metabolism and microbes, environmental exposures, and lifestyle factors, to predict how different patients will respond to various therapies. In theory, this will allow for highly tailored, personalized therapy plans with superior efficacy and minimal side effects.

Beyond pharmacogenomics, AI’s role in personalized medicine expands to precision dosing and disease prediction/prevention, including AI-powered risk assessment and lifestyle recommendations.

3. Clinical Trials

Clinical trials are riddled with issues and are known to be highly time- and cost-intensive. AI has the potential to optimize clinical trial design and execution in multiple ways. Among others, ML algorithms can predict trial outcomes, write protocols, optimize eligibility criteria, identify and recruit the most suitable candidates for trials, monitor patient health remotely, and analyze data. When used to augment human-centric efforts such as virtual patient and provider insight-gathering, AI tools could help recruit and retain more diverse participants, improve the efficiency and effectiveness of clinical trials, lower the associated costs, and expedite the drug development process.

4. Manufacturing Optimization

Close-up of the pharmaceutical manufacturing process; AI could play a role in optimizing this process.While the manufacturing industry lags behind others in terms of AI uptake, there is no shortage of potential ways to leverage this technology. AI can be used to improve the efficiency of pharmaceutical manufacturing processes through ongoing monitoring and predictive maintenance of equipment, optimization of production processes, and automated quality control, helping to reduce costs and improve yield. It also has the potential to reduce the high carbon footprint associated with manufacturing.

 

5. Supply Chain Management

Due to geopolitical and climate-related challenges, Pharma supply chain disruptions are becoming increasingly common and complex. AI algorithms can analyze extensive datasets in real-time to efficiently and dynamically forecast demand fluctuations, optimize production schedules, and proactively avoid bottlenecks in the Pharma supply chain. In turn, this can support decision-making and lead to more efficient inventory management and faster delivery times, enhance supply chain visibility and transparency, and avoid overproduction and waste.

Interestingly, a 2023 study found that, in emerging markets, technological factors, including technology infrastructure and feasibility to implement or adopt AI at an organizational level, are the most influential factors impacting AI adoption in the healthcare supply chain, followed by institutional or environmental, human, and organizational dimensions

6. Real-World Evidence (RWE)

Real-word data from electronic health records, insurance claims, wearables, social media, and other sources can provide important insights into real-life drug performance, patient adherence, and market trends to inform better decision-making. In 2020, McKinsey estimated that over the next 3–5 years, the average top-20 Big Pharma company could unlock over $300 million a year by adopting advanced RWE analytics across its value chain. This technology could help identify new drug targets, shorten the time to market, improve formulary position and payer negotiations, and generate stronger evidence of differentiation and benefit/risk balance for in-market products. However, despite the great promise, many companies still struggle to deploy AI and advanced analytics effectively to generate RWE.

7. Digital Therapeutics and Patient Monitoring

Image showing a woman's torso and arms; she is wearing a wearable device (smart watch) that monitors her vitals. Such wearables can be connected with AI.Patient health, behavioral, and outcome data from digital therapeutics and remote patient monitoring, including wearable devices, can be effectively analyzed using advanced analytics and AI to identify patterns, trends, and predictive insights. As a result, AI-powered monitoring tools can provide patients with personalized treatment recommendations while continuously monitoring their health and alerting healthcare providers to potential issues in real time. Studies have shown that this has the potential to not only improve clinical outcomes, reduce the incidence of complications, and shorten hospital stays, but also to improve patient satisfaction.

8. Regulatory Compliance

Regulatory frameworks are continuously evolving in the pharmaceutical industry. To avoid compliance issues, it is essential to keep up with new regulatory changes, including updated reporting guidelines and safety requirements. AI and Natural Language Processing tools can help Pharma companies navigate the increasingly complex regulatory landscape through regulatory intelligence and by automating the compilation and review of regulatory documents, predicting regulatory risks, and ensuring compliance with global standards.

9. Market Analysis and Competitive Intelligence

AI tools can analyze vast amounts of data from various sources to provide insights into market trends, competitor activities, and emerging opportunities. By automating these tedious manual assessments, AI can substantially widen the scope of evaluation and help Pharma companies make more informed strategic decisions and optimize their drug launches.

10. Drug Repurposing

Lastly, AI could play a role in drug repurposing, i.e., the use of approved or investigational drugs to treat conditions other than the one they were initially developed for. Drug repurposing has the benefit of delivering safe and effective therapeutics to patients much faster and cost-efficiently than a de novo therapeutic, and AI can speed this process up even more by identifying new and promising targets. Specifically, AI can help with data mining and integration, predictive modeling and virtual screening, network pharmacology and systems biology, clinical trial optimization, safety and toxicity prediction, and decision support.

Importance of the Human Touch

As AI technology continues to evolve, its applications in the pharmaceutical industry are likely to expand, offering new opportunities to improve health outcomes and transform business operations. However, while great progress has been made lately, it is important to keep in mind that AI should only supplement, never replace, human efforts. Just like asking AI to help me outline and find references for (but not write) this article saved me countless hours that can now be used on something else, Pharma can leverage the vast array of AI tools to enhance their own productivity and optimize their operations.

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Helping Patients Become Active Participants in Their Own Care

Rishi Nayyar, Co-founder & CEO of PocketHealth, explores how releasing medical imaging records straight to patients can result in data moving more ethically, easily, and securely. He also shares his...

Virtual Speaker Program: A Customer Story

Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions.

Impact of COVID-19 on the Biopsychosocial Model of Health

Dr. Tarry Ahuja, Manager of Program Development in Pharmaceutical Reviews and Senior RWE Advisor at CADTH, explores the impact of COVID-19 on the biopsychosocial model of health, key opportunities and...

Leaders in Pharma: Fran Milnes

In this episode of Impetus Digital's Leaders in Pharma podcast, I sit down with Fran Milnes. She is currently the Head of Marketing and Commercial Excellence in Oncology at Novartis.

FREE eBook: The Complete Guide to Virtualizing In-person Meetings

Download our latest eBook for free to learn about the innovative ways clients have used our synchronous and asynchronous virtual tools to engage participants and virtualize their meetings and events.

Open-Data Platforms for Direct Engagement with Patients, Researchers, and Pharma

Indu Navar, CEO and Founder of EverythingALS, explores the roles of Artificial Intelligence, Machine Learning, and Brain Computer Interface in the search for a cure for ALS. She will also...

Moving Away from Hospital-Centered Care: Barriers & Opportunities

David Barthel, CEO of Health Logic Interactive Inc., discusses their lab-on-chip, point-of-care platform technology for CKD. He also explores the issues with the hospital-centered model of care, shares his tips...

MSL Digital Offices and HCP Community Boards: A Customer Story

Learn how our client is leveraging the Impetus InSite Platform® to host company-wide “digital offices” and community boards for MSLs and HCPs to connect one-on-one or one-to-many.

Breaking Down the Wall: Blockchain in Healthcare and Pharma

Ray Dogum, Senior Consultant and Blockchain Strategist at ConsenSys Health and Podcaster at Health Unchained, explores blockchain in Pharma and healthcare, including innovative use cases, current barriers, and how to...

Building Better Patient Advocates Through Authentic Partnerships

Sabrina Hanna, Founder & CIO of the Cancer Collaborative, discusses precision medicine, innovation in oncology, how to build better patient advocates, and the current gaps when it comes to patient-centricity...